Crossmark

Sebetralstat: FDA approves first oral on-demand therapy for hereditary angioedema

Crossref DOI link: https://doi.org/10.1007/s11845-025-04153-6

Published Online: 2025-11-05

Published Print: 2026-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bibi, Laiba https://orcid.org/0009-0003-0566-9168
Azam, Hafsa https://orcid.org/0009-0007-6357-9389
Yaseen, Fatima https://orcid.org/0009-0006-9201-3715
License Information

Text and Data Mining valid from 2025-11-05

Version of Record valid from 2025-11-05
More Information

Article History

Received: 18 July 2025

Accepted: 26 October 2025

First Online: 5 November 2025

Declarations

:

: The authors declare no competing interests.